E Schulte-Frohlinde
Overview
Explore the profile of E Schulte-Frohlinde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sternfeld T, Spori-Byrtus V, Riediger C, Langer R, Friess H, Schmid R, et al.
Int J Infect Dis
. 2009 Sep;
14(6):e528-30.
PMID: 19729330
We report the case of a 31-year-old immunosuppressed, liver transplanted man, with acute measles infection. The vaccinated patient had been exposed to measles during a known measles epidemic in public...
2.
3.
von Delius S, Lersch C, Mayr M, Stock K, Schulte-Frohlinde E, Schmid R, et al.
Hepatogastroenterology
. 2008 Feb;
54(80):2310-4.
PMID: 18265654
Background/aims: Patients with advanced hepatocellular carcinoma (HCC) face a dismal prognosis, as no effective palliative chemotherapy exists. Moreover, treatment of patients with hepatocellular carcinoma presents a major challenge, because associated...
4.
Hillerer C, Schulte-Frohlinde E, Dobritz M, Gaa J
Radiologe
. 2007 Sep;
47(2):163-4, 166.
PMID: 17891851
The Abernethy malformation is a rare anomaly with partial or complete congenital absence of the portal vein and subsequent development of extrahepatic portocaval shunts. Diagnosis is usually made in childhood...
5.
Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver
von Delius S, Lersch C, Schulte-Frohlinde E, Fend F, Dobritz M, Schmid R, et al.
Z Gastroenterol
. 2006 Jan;
44(1):39-42.
PMID: 16397838
The occurrence of primary hepatocellular carcinoma (HCC) in patients with hereditary hemochromatosis (HH) is well known. Thereby, the development of liver cirrhosis seems to be a prerequisite. Whether or not...
6.
Eckel F, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, et al.
Oncology
. 2005 Dec;
69(5):363-71.
PMID: 16319507
Objectives: No effective chemotherapy for advanced hepatocellular carcinoma (HCC) exists. Expression of the platelet-derived growth factor receptor (PDGFR) has been demonstrated in HCC, which may derive from hepatic stem cells...
7.
Simon G, Link T, Wortler K, Doebereiner F, Schulte-Frohlinde E, Daldrup-Link H, et al.
Eur Radiol
. 2005 Apr;
15(5):895-903.
PMID: 15800773
The aim was to compare the diagnostic performance of dynamic Gd-DTPA- and ferumoxides-enhanced MRI for hepatocellular carcinoma (HCC). Twenty-five patients with chronic hepatitis or liver cirrhosis underwent both dynamic gadopentetate-...
8.
Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, et al.
Hepatogastroenterology
. 2004 Jul;
51(58):1099-103.
PMID: 15239254
Background/aims: New perspectives in the treatment of advanced hepatocellular carcinomas have recently been inaugurated with the application of hydroxymethylglutaryl coenzyme A reductase inhibitors i.e. pravastatin, the somatostatin analogue octreotide, or...
9.
Eckel F, Lersch C, Lippl F, Schulte-Frohlinde E, Schusdziarra V, Helmberger H, et al.
Scand J Gastroenterol
. 2002 Sep;
37(8):972-7.
PMID: 12229975
Background: Positron emission tomography (PET) determines therapy-induced changes in tumour glucose utilization. Experimental data indicate that cholecystokinin (CCK) stimulates pancreatic cancer growth. In this study in patients with advanced pancreatic...
10.
Eckel F, Lersch C, Lippl F, Assmann G, Schulte-Frohlinde E
J Exp Clin Cancer Res
. 2001 Jan;
19(3):295-300.
PMID: 11144522
Leucovorin modulates the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. 24-hour infusion of 5-FU has been shown to enhance antitumor activity in colorectal cancer compared to bolus...